NOVO NORDISK INC.

Lobbying for NOVO NORDISK INC.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $1,730,000.00 expenses · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 150
Affordable Prescriptions for Patients Act of 2023

Lobbying activity 6

Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding

Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill

Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around Most Favored Nation drug pricing

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding

Taxation/Internal Revenue Code

International and corporate tax, H.R. 1 One Big Beautiful Bill

Tariff (miscellaneous tariff bills)

Discussed potential tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.